GLP-1-based therapy for diabetes: what you do not know can hurt you.
Butler
Peter C
PC
Dry
Sarah
S
Elashoff
Robert
R
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D009765:Obesity / Q000150:complications; D047495:PPAR gamma / Q000819:agonists; D010190:Pancreatic Neoplasms / Q000453:epidemiology; D018570:Risk Assessment; D012449:Safety
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D052216:Glucagon-Like Peptide 1